Alnylam Provides Timing for New Pipeline Programs, Inks Two Deals for Biotherapeutics Initiative
February 24, 2011
Alnylam Provides Timing for New Pipeline Programs, Inks Two Deals for Biotherapeutics Initiative
After undergoing a makeover of sorts last month when the company unveiled a new product-development strategy, this week it said it remains on track to have five candidates in “advanced” clinical development by 2015.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RXi Q1 Loss Rises on Opko Deal Charge
May 16, 2013 / Gene Silencing News - Alnylam to Release Phase II ATTR Data, Launch Expansion Trial in Coming Months
May 9, 2013 / Gene Silencing News - Alnylam Finds Partner for Cholesterol Program in The Medicines Company
February 7, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to UNC, Alnylam, FSU, and More
February 7, 2013 / Gene Silencing News - Alnylam ATTR Program on Track as Company Explores Subcutaneous Delivery for Cholesterol Drug
November 8, 2012 / Gene Silencing News